Intrathecal administration of levetiracetam
AssigneeSintetica S.A.
InventorsAugusto Mitidieri, Elisabetta Donati, Clara Bianchi, Barbara Piccagli
Life of this patent
Estimating the term…
Abstract
Methods of treatment, pharmaceutically acceptable solutions, and implantable devices are provided for the intrathecal treatment of AED-resistant seizures using levetiracetam.
Claims20
A method of treating or preventing seizures in a human patient in need thereof comprising centrally administering to said patient a therapeutically effective amount of a pharmaceutically acceptable solution comprising levetiracetam or a pharmaceutically acceptable salt thereof, wherein said seizures are resistant to treatment by systemically administered levetiracetam or two or more systemically administered anti-epileptic drugs other than levetiracetam, wherein the solution is administered continuously or intermittently via an implantable delivery device, at a delivery rate of from 2 to 500 mg levetiracetam per day, and wherein the solution comprises from 2.5 to 60 mg/ml of levetiracetam in water.
A method of treating or preventing frequent debilitating seizures in a human patient in need thereof comprising intrathecally administering to said patient a therapeutically effective amount of a pharmaceutically acceptable solution comprising levetiracetam or a pharmaceutically acceptable salt thereof, wherein the solution is administered continuously or intermittently via an implantable delivery device, at a delivery rate of from 20 to 1000 mg levetiracetam per day, and wherein the solution comprises from 2.5 to 60 mg/ml of levetiracetam in water.
A substantially isotonic intrathecal pharmaceutically acceptable solution comprising from 2.5 to 60 mg/ml of levetiracetam in water, buffered at a pH of from 5 to 7.
A method of treating or preventing seizures in a human patient in need thereof comprising centrally administering to said patient a therapeutically effective amount of a pharmaceutically acceptable solution comprising levetiracetam or a pharmaceutically acceptable salt thereof, wherein said seizures are resistant to treatment by systemically administered levetiracetam or two or more systemically administered anti-epileptic drugs other than levetiracetam, wherein the solution is administered continuously or intermittently via an implantable delivery device, at a delivery rate of from 2 to 500 mg levetiracetam per day, and wherein said levetiracetam is administered intrathecally through a catheter tip inserted in the cervical region of the spine from the C1 to the C3 vertebrae.
A method of treating or preventing frequent debilitating seizures in a human patient in need thereof comprising intrathecally administering to said patient a therapeutically effective amount of a pharmaceutically acceptable solution comprising levetiracetam or a pharmaceutically acceptable salt thereof, wherein the solution is administered continuously or intermittently via an implantable delivery device, at a delivery rate of from 20 to 1000 mg levetiracetam per day, and wherein said levetiracetam is administered intrathecally through a catheter tip inserted in the cervical region of the spine from the C1 to the C3 vertebrae.
Dependencies are inferred from the claim text.